We are having trouble showing you adverts on this page, which may be a result of ad blocker software being installed on your device. As Business Matters relies on advertising to fund its journalism, please disable any adblockers from running on BMmagazine.co.uk to see the rest of this content.

 
Glaxo fined £37.6m for ‘illegal behaviour’ over Seroxat deals

Glaxo fined £37.6m for ‘illegal behaviour’ over Seroxat deals

UK competition watchdog said firm paid drugmakers £50m in return for delaying cheaper generic versions of drug

 

More in News Wire